Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

News Conference News SCAI 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

May 25, 2023

Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD

News Conference News ESC 2021

Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD

Michael O'Riordan

August 29, 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

News Conference News ACC 2021

Rivaroxaban Helps Prevent More Events Than Aspirin Alone After Leg Interventions

May 21, 2021

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

News Conference News ACC 2018

COMPASS Approach Helps With Leg Complications in Patients With PAD

March 12, 2018

Clinician-Patient Mismatch: How to Get Past the Imbalance in Knowledge (and Power)

News Conference News ISET 2018

Clinician-Patient Mismatch: How to Get Past the Imbalance in Knowledge (and Power)

February 16, 2018

Plaque Attack: Options Evolve for Imaging Coronaries and Carotids, but Link With Hard Outcomes Remains Elusive

News Conference News EAS 2017

Plaque Attack: Options Evolve for Imaging Coronaries and Carotids, but Link With Hard Outcomes Remains Elusive

Yael L. Maxwell

May 01, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.